• Associated diseases/conditions:

Non-small cell lung cancer (NSCLC)

 

Potential Biomarkers:

Insulin-like growth factor (IGF) pathway

 

Detections:

Protein expressions, serum levels

 

Potential Applications:

Predictive biomarkers (tumor progression and patient outcomes)

 

References:

Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov;92(5):1805-11; discussion 1811. doi: 10.1016/j.athoracsur.2011.06.058. (http://www.ncbi.nlm.nih.gov/pubmed/21945224)

 

  • Associated diseases/conditions:

Non-small cell lung cancer (NSCLC)

 

Potential Biomarkers:

Epidermal growth factor receptor (EGFR) pathway

 

Detections:

Mutations, lymph nodes

 

Potential Applications:

“Diagnostic biomarkers for tumor heterogeneity (between primary tumors and lymph node metastasis)”

 

References:

Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4. (http://www.ncbi.nlm.nih.gov/pubmed/19487967)

 

  • Associated diseases/conditions:

Colorectal cancer

 

Potential Biomarkers:

APC/β-catenin signaling pathway

 

Detections:

Expressions in mucosa from the rectum and colon

 

Potential Applications:

“Treatable, preneoplastic biomarkers of risk for colorectal neoplasms”

 

References:

Ahearn TU, Shaukat A, Flanders WD, Seabrook ME, Bostick RM. Markers of the APC/β-catenin signaling pathway as potential treatable, preneoplastic biomarkers of risk for colorectal neoplasms. Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):969-79. doi: 10.1158/1055-9965.EPI-12-0126. (http://www.ncbi.nlm.nih.gov/pubmed/22539608)

 

  • Associated diseases/conditions:

Head and neck squamous cell carcinoma (HNSCC)

 

Potential Biomarkers:

Phosphoinositide 3-kinase (PI3K) pathway

 

Detections:

Frequent mutations in tumors

 

Potential Applications:

“Predictive biomarkers for treatment selection (mTOR/PI3K inhibitor (BEZ-235))”

 

References:

Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul;3(7):761-9. doi: 10.1158/2159-8290.CD-13-0103.  (http://www.ncbi.nlm.nih.gov/pubmed/23619167)

 

  • Associated diseases/conditions:

Squamous carcinoma

 

Potential Biomarkers:

Interferon (IFN)/STAT1 and neuregulin signaling pathways

 

Detections:

mRNAs expressions, tumor cell-line models

 

Potential Applications:

“Predictive biomarkers for treatment response (to cetuximab (Erbitux®))”

 

References:

Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S,  Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. (http://www.ncbi.nlm.nih.gov/pubmed/21833472)

 

  • Associated diseases/conditions:

Colorectal cancer

 

Potential Biomarkers:

Wnt signaling pathway

 

Detections:

Tag single nucleotide polymorphisms (tSNPs) in adenomatous polyposis coli

 

Potential Applications:

Prognostic biomarkers for outcome prediction

 

References:

Ting WC, Chen LM, Pao JB, Yang YP, You BJ, Chang TY, Lan YH, Lee HZ, Bao BY. Common genetic variants in Wnt signaling pathway genes as potential prognostic biomarkers for colorectal cancer. PLoS One. 2013;8(2):e56196. doi: 10.1371/journal.pone.0056196. (http://www.ncbi.nlm.nih.gov/pubmed/23405266)

 

  • Associated diseases/conditions:

IBD-associated colorectal carcinogenesis

 

Potential Biomarkers:

Wnt-pathway activation

 

Detections:

Protein expressions, tissue microarray with colonic samples

 

Potential Applications:

Early diagnostic biomarkers

 

References:

Claessen MM, Schipper ME, Oldenburg B, Siersema PD, Offerhaus GJ, Vleggaar FP. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol. 2010 Jan 1;32(4):303-10. doi: 10.3233/CLO-2009-0503. (http://www.ncbi.nlm.nih.gov/pubmed/20208143)

 

  • Associated diseases/conditions:

Epithelial ovarian cancer

 

Potential Biomarkers:

Wnt pathway

 

Detections:

DNA methylation (epigenetic regulations) at promoter CpG islands (CGI), from epithelial ovarian tumors

 

Potential Applications:

“Predictive biomarkers of patient progression-free survival (PFS)”

 

References:

Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. (http://www.ncbi.nlm.nih.gov/pubmed/21459799)

Leave a Reply

Copyright © 2006-2017 PharmTao.com. All Rights Reserved.

Disclaimer: By using this site, the readers agree that the content on our web pages is for information purpose only. The information provided on our web pages is not intended for diagnosis, or to treat, cure or prevent any diseases, conditions or symptoms, or to endorse any products. Personal directions and the use of health products should be provided by qualified health professionals.

Mind-Body, Personalized, and Systems Medicine